Showing results (31-40 of 45) with videos related to
Sort By:
Pageof 5
Bioorganic & Medicinal Chemistry Letters|February 23, 2016
Identification of potent and selective MTH1 inhibitorsAlessia Petrocchi, Elisabetta Leo, Naphtali J Reyna, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2022
Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and TrapperGiuditta Illuzzi, Anna D Staniszewska, Sonja J Gill, et al.Journal of Hematology & Oncology|November 7, 2021
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA statusFrancesca Bizzaro, Ilaria Fuso Nerini, Molly A Taylor, et al.Journal of Medicinal Chemistry|June 11, 2015
Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain InhibitorWylie S Palmer, Guillaume Poncet-Montange, Gang Liu, et al.Epigenetics & Chromatin|September 24, 2015
Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discoveryYanai Zhan, Maria Kost-Alimova, Xi Shi, et al.British Journal of Cancer|October 19, 2021
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage responseSophie E Willis, Claudia Winkler, Martine P Roudier, et al.Cancer Research|July 4, 2015
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor StudiesBhavatarini Vangamudi, Thomas A Paul, Parantu K Shah, et al.Neuro-Oncology|December 24, 2025
Subtype selective PET imaging of PARP1 binding in non-human primates, healthy volunteers and patients with glioblastoma using [11C]AZ14193391Zsolt Cselényi, Aurelija Jucaite, Giuseppe Stragliotto, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2023
Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1Anna D Staniszewska, Domenic Pilger, Sonja J Gill, et al.Genome Medicine|August 26, 2024
The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer modelsAndrea Herencia-Ropero, Alba Llop-Guevara, Anna D Staniszewska, et al.Pageof 5